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A B S T R A C T
Background
Knowledge of the number of recent HIV infections is important for epidemiologic
surveillance. Over the past decade approaches have been developed to estimate this number
by testing HIV-seropositive specimens with assays that discriminate the lower concentration
and avidity of HIV antibodies in early infection. We have investigated whether this ‘‘recency’’
information can also be gained from an HIV confirmatory assay.
Methods and Findings
The ability of a line immunoassay (INNO-LIA HIV I/II Score, Innogenetics) to distinguish recent
from older HIV-1 infection was evaluated in comparison with the Calypte HIV-1 BED Incidence
enzyme immunoassay (BED-EIA). Both tests were conducted prospectively in all HIV infections
newly diagnosed in Switzerland from July 2005 to June 2006. Clinical and laboratory
information indicative of recent or older infection was obtained from physicians at the time of
HIV diagnosis and used as the reference standard. BED-EIA and various recency algorithms
utilizing the antibody reaction to INNO-LIA’s five HIV-1 antigen bands were evaluated by
logistic regression analysis. A total of 765 HIV-1 infections, 748 (97.8%) with complete test
results, were newly diagnosed during the study. A negative or indeterminate HIV antibody
assay at diagnosis, symptoms of primary HIV infection, or a negative HIV test during the past 12
mo classified 195 infections (26.1%) as recent ( 12 mo). Symptoms of CDC stages B or C
classified 161 infections as older (21.5%), and 392 patients with no symptoms remained
unclassified. BED-EIA ruled 65% of the 195 recent infections as recent and 80% of the 161 older
infections as older. Two INNO-LIA algorithms showed 50% and 40% sensitivity combined with
95% and 99% specificity, respectively. Estimation of recent infection in the entire study
population, based on actual results of the three tests and adjusted for a test’s sensitivity and
specificity, yielded 37% for BED-EIA compared to 35% and 33% for the two INNO-LIA
algorithms. Window-based estimation with BED-EIA yielded 41% (95% confidence interval
36%–46%).
Conclusions
Recency information can be extracted from INNO-LIA-based confirmatory testing at no
additional costs. This method should improve epidemiologic surveillance in countries that
routinely use INNO-LIA for HIV confirmation.
The Editors’ Summary of this article follows the references.
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Introduction
Assessment of the number of individuals with early HIV
infection is needed for evaluation of the current HIV
epidemic and preventive efforts targeted at the different
transmission risk populations. Consequently, serologic testing
algorithms for recent HIV seroconversion (STARHS) have
been developed. These tests utilize the fact that both the
concentration and afﬁnity of HIV antibodies in early
infection are lower than at later stages [1,2]. The fact that
STARHS requires a special assay, which has a deliberately
reduced sensitivity compared to HIV screening tests, restricts
STARHS to epidemiologic studies. However, for systematic
epidemiologic monitoring it would be advantageous if
‘‘recency’’ information (i.e. how recently the infection was
acquired) could be simultaneously gained from the same tests
being used to diagnose HIV infection.
Here we have investigated whether a second-generation
Western blot assay (line immunoassay) provides recency
information similar to that of a commercially available
STARHS test, which is used for estimating the incidence of
recent infections in a population and was originally devel-
oped by researchers at the US Centers for Disease Control
and Prevention (CDC) [3]. The line immunoassay features
standardized antigens of both HIV-1 and HIV-2 and three
internal controls. It is currently being used increasingly as a
replacement for the traditional ﬁrst-generation HIV Western
blot developed more than 20 years ago [4,5]. The test has
recently become mandatory for conﬁrmation of HIV in-
fection and differentiation of HIV-1 and HIV-2 in Switzer-
land [6].
Methods
Patients and Specimens
It is estimated that several hundred thousand HIV screen-
ing tests are performed annually in Switzerland. Serum or
plasma specimens from all individuals in whom HIV infection
was newly diagnosed in Switzerland between 1 July 2005 and
30 June 2006 were selected for the study. By federal
ordinance, an epidemiologic questionnaire on each newly
diagnosed HIV infection has to be forwarded under code to
the Swiss Federal Ofﬁce of Public Health (SFOPH) by the
patient’s physician. Of relevance to the present study, the
questionnaire contains items about clinical or laboratory
signs of recent infection (e.g., symptoms of primary HIV
infection, CDC staging [7], and seroconversion).
Definition of Recent or Older Infection
For the purpose of this study an HIV infection was deﬁned
as recent on the basis of the physicians’ information reported
to the SFOPH and by the laboratory results obtained at the
time of diagnosis of the HIV infection. Speciﬁcally, a recent
infection was required to meet one or more of the following
conditions. Deﬁnition 1: signs of primary HIV infection (PHI)
at the time of diagnosis [8]; deﬁnition 2: a self-reported or
documented negative result of a HIV screening test within 12
mo before HIV diagnosis; or deﬁnition 3, laboratory evidence
of seroconversion at the time of diagnosis, i.e., a reactive
fourth-generation HIV-1/2/O antibody/antigen combination
screening test and a positive virus component test (HIV-1 p24
antigen or HIV-1 RNA) combined with a negative or
indeterminate antibody assay (third-generation HIV-1/2/O
antibody enzyme immunoassay, Western blot, or INNO-LIA).
The time window during which an infection was deﬁned as
being recent thus was 12 mo. An infection was deﬁned as
older if symptoms of CDC stages B or C were present at the
time of diagnosis and reported to the SFOPH [7]. Report of
no symptoms (CDC stage A) or lack of staging information
remained undeﬁned and were either excluded from or
included in the analysis depending on the respective
evaluation as described under results.
Tests for Recent HIV-1 Infection
All study samples were tested prospectively by the INNO-
LIA HIV I/II Score assay (Innogenetics, Ghent, Belgium) in
one of the 11 accredited Swiss HIV Conﬁrmatory Labs or the
Swiss National Center for Retroviruses (SNCR), the later
being commissioned by the SFOPH to serve as the national
HIV reference laboratory. INNO-LIA tests were conducted as
a mandatory component of the SFOPH HIV testing system
[6]. The INNO-LIA HIV I/II Score assay (INNO-LIA) is a
Western blot–like line immunoassay that measures antibodies
against recombinant proteins or synthetic peptides of HIV-1,
HIV-1 group O, or HIV-2, which are coated as discrete lines
on a nylon strip with plastic backing. As each test strip also
contains three quantitative internal standards, a semiquanti-
tative ranking of the different antibody reactions is possible
[9,10].
All INNO-LIA assays were performed by trained laboratory
personnel using the manufacturer’s 16-h sample incubation
protocol. Antibody reaction to each of the seven HIV antigen
bands present on the INNO-LIA test strip (sgp120 [including
group O peptides], gp41, p31, p24 and p17 of HIV-1, and
sgp105 and gp36 of HIV-2) was assessed visually in nine
laboratories and by the automated scanner–based LiRAS
system (Innogenetics) in three laboratories. Based on the
three internal standards, which deﬁne reaction levels of 0.5
(þ/), 1, and 3, the antibody reaction to each HIV antigen was
classiﬁed intooneof sixpossible intensity scores (0, 0.5 [forþ/],
1, 2, 3, or 4) according to the manufacturer’s instructions.
Frozen aliquots (20 8C) of all samples were furthermore
sent under code to the SNCR and tested prospectively by the
HIV-1 BED Incidence enzyme immunoassay (BED-EIA,
Calypte Biomedical Corporation, Lake Oswego, Oregon,
United States). BED-EIA was performed as a part of an
ethically approved nationwide epidemiologic study (CH.A.T.
survey) commissioned by the SFOPH. It aimed at elucidating
the circumstances under which new HIV infections in
Switzerland occurred (see http://www.bag.admin.ch/hiv_aids/
00829/03471/index.html?lang¼de for further information). All
BED-EIA testing was performed in blinded fashion by a
single, highly experienced person and using a Microsoft
Excel-based program for automated result interpretation
prepared for the study according to Calypte’s instructions,
which specify a cutoff of 0.8 normalized optical density units
(ODn).
Determination of INNO-LIA Window Periods
Window periods for INNO-LIA recency algorithms were
determined based on results with 15 seroconversion panels
with a total of 105 specimens (Boston Biomedica, West
Bridgewater, Massachusetts, United States; panels PRB 903–
904, 909–912, 916–919, 922–925, and 927). The INNO-LIA
results on these panels were provided by Innogenetics. The
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raw window period was calculated as the difference in days
between the ﬁrst sample reactive in the most sensitive third-
generation HIV-1/2 screening test (based on data from Boston
Biomedica) and the ﬁrst sample ruled ‘‘older’’ by the
respective INNO-LIA recency algorithm. To these raw
window periods was added a constant of 22 d, which
corresponds to the estimated median seroconversion window
of sensitive third-generation HIV-1/2 screening assays [11].
Statistical Evaluation
Differences in INNO-LIA reaction intensity in different
study subgroups, as assessed in Figure 1, were compared by
unpaired t-test. Speciﬁcity, sensitivity, diagnostic odds ratio,
and logistic likelihood ratio of the BED-EIA and various
tentative INNO-LIA HIV I/II Score algorithms for recency, as
presented in Tables 1–3, were calculated by means of
contingency tables and univariate and multivariate logistic
regression analysis, as implemented by the StatView 5.0
program for Macintosh (SAS Institute, Cary, North Carolina,
United States). Physicians’ information was used as the
reference standard for recency in all such evaluations.
Estimates for the recent infection rates in Table 4 were
obtained by the equation Recency Rate¼ (ntested recent/ntestedþ
%Speciﬁcity/100 1) / (%Sensitivity/100þ%Speciﬁcity/100
1). This equation is based on the relationship ntested recent ¼
ntrue-recentþ nfalse-recent, wherein ntrue-recent¼ ntested3 Recency
Rate3%Sensitivity/100 and nfalse-recent¼ntested3 (1Recency
Rate)3 (1%Speciﬁcity/100). Window-based estimates of the
recent infection rate were performed by the equation (nrecent/
748)3 (365/Window), shown with Table 5.
Results
A total of 765 newly diagnosed HIV infections were
reported to the SFOPH during the 12 mo of the study (July
05–June 06). Seventeen cases were excluded due to missing
Figure 1. Antibody Reaction as Assessed by the INNO-LIA in Different Groups of Newly Diagnosed HIV-1 Patients
(A) Sum of antibody scores to env antigens sgp120 and gp41 (top graph), gag antigens p24 and p17 (middle graph) and pol antigen p31 (bottom
graph); bars represent means and error bars their 95% confidence intervals. Reaction is stratified according to recency definitions 1, 2, or 3 and other
reported staging information (see Methods).
(B) Correct order of recency definitions based on increasing antibody development. Box plots show sum of antibody scores to all five HIV-1 antigen
bands. Boxes indicate the median and the 25th and 75th percentile. Horizontal lines located outside of, but closest to the boxes represent the 10th and
90th percentile, respectively. Outliers are plotted individually. The medians of the groups consisting of infections not classified coincide with the 75th
percentile (upper limit of box). p-Values on top denote differences between subgroups of recent infections.
doi:10.1371/journal.pmed.0040343.g001
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INNO-LIA results, thus leaving a total of 748 patients for
evaluation (97.8%). All infections were by HIV type 1. A total
of 195 patients met the deﬁnition of a recent infection as
described in Methods, and 161 patients met the deﬁnition of
an older infection. Of these, 84 were reported to be in CDC
stage B and 77 in stage C. Remaining unclassiﬁed were 392
patients, 252 without symptoms (stage A) and 140 with no
information provided. The main characteristics of the study
population are summarized in Table 6.
INNO-LIA Reactivity in Dependence of Stage
INNO-LIA reactivity to env bands sgp120þgp41, gag bands
p17þp24, and pol p31 in the different groups is summarized
in Figure 1A. Infections deﬁned as recent had lower mean
antibody intensities to all antigens compared to all other
groups (p , 0.001 in all comparisons). Those with both
symptoms of PHI and a reported negative HIV test within the
past 12 mo (thus meeting both recency deﬁnitions 1 and 2)
had lower antibodies on average than those with reported
PHI but no negative HIV test (recency deﬁnition 1), and the
latter in turn had lower antibody levels than those with a
history of a negative HIV test but no PHI symptoms (recency
deﬁnition 2). Thus, those with both symptoms of PHI and a
reported negative test represented an early phase, those with
PHI symptoms alone an intermediate phase, and those with a
documented negative test alone a late phase of recent
infection (Figure 1B). Moreover, infections deﬁned as recent
based on their negative or indeterminate results in HIV
antibody tests at the time of diagnosis (recency deﬁnition 3)
showed the lowest antibody reactivity of all, thus classifying
themselves as the most recent infections. Figure 1B also shows
the p-values for the differences between the various sub-
groups of recent infection.
Antibody reactions in CDC stage A were similar to those in
stages B or C except that antibodies to gag antigens were
slightly higher than in stage C (p ¼ 0.01), in agreement with
established knowledge [12,13]. The 140 cases with no
information were indistinguishable as a group from CDC
stage A (Figure 1B) and like A exhibited a trend for higher
Table 1. Performance of Various Algorithms for Detecting Recent Infection among Cases of Defined Recency Status
Alg # Algorithm Criteria Sensitivity,
%
Specificity,
%
Overall
Correct, %
Odds Ratio
(95% CI)
Logistic
Likelihood
Ratio Chi-Square
1 BED-EIA 65.1 80.1 71.9 7.4 (4.6–12.2) 76.7
2 sgp120  1 41.5 95.7 66.0 15.6 (7.0–35.1) 75.9
3 gp41  0.5 20.0 100 56.2 NC 50.9
4 p31 ¼ 0 49.2 93.8 69.4 14.6 (7.3–29.5) 88.3
5 p24 ¼ 0 21.0 98.1 55.9 14.0 (4.2–46.2) 35.9
6 p17 ¼ 0 32.8 91.9 59.6 5.6 (2.9–10.6) 34.6
7 sgp120þgp41þp31  4 40.5 98.1 66.6 35.9 (11.0–116) 91.2
8 gp41  0.5; or sgp120þgp41þp31  4; or
sgp120þgp41þp31þp24þp17  6.5
41.5 98.1 67.1 37.4 (11.5–121) 94.5
9 sgp120þgp41  4 and p31 ¼ 0 40.0 98.8 66.6 53.0 (12.7–220) 95.4
10 p31¼0 and p24  2 24.1 96.3 65.7 8.2 (3.4–19.8) 32.9
11 sgp120þgp41  2.5;
or sgp120þgp41þp31þp24þp17  6.5; or p31 ¼ 0
and p24  2
49.7 95.0 70.2 18.9 (8.8–40.7) 97.9
12 gp41  0.5; or sgp120þgp41þp31  4; or
sgp120þgp41þp31þp24þp17  6.5; or p31 ¼ 0
and p24  2
50.3 95.0 70.5 19.3 (9.0–41.5) 99.6
13 sgp120þgp41  4 and p31 ¼ 0; or
p31 ¼ 0 and p24  2
48.7 95.7 69.9 20.9 (9.3–46.9) 98.7
Algorithms 2–13 are I INNO-LIA HIV I/II Score-based. Of 356 patients, 195 (54.8%) were recent and 161 (45.2%) were older.
NC, cannot be calculated.
doi:10.1371/journal.pmed.0040343.t001
Table 2. Diagnosis of Recent Infection and Test Concordance in Dependence of Stage
Stagea n,
Total
Recent by BED-EIA Recent by INNO-LIA Alg12 Recent by Both Older by Both Test Concordance
n % n % % % %
Defined as recent 195 127 65.1 98 50.3 44.6 29.2 73.8
Not classified, CDC stage A 252 63 25.0 17 6.7 4.4 72.6 77.0
Not classified, no information 140 40 28.6 7 5.0 4.3 70.7 75.0
Defined as older, CDC stage B 84 20 23.8 3 3.6 2.4 75.0 77.4
Defined as older, CDC stage C 77 12 15.6 5 6.5 3.9 81.8 85.7
aSee Methods for explanation of stages.
doi:10.1371/journal.pmed.0040343.t002
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antibodies to gag antigens compared to CDC stage C (for p17,
p ¼ 0.053).
Prediction of Recent Infection in Patients with Defined
Recency Status
A ﬁrst evaluation of recency prediction by BED-EIA or
INNO-LIA was based on the 356 cases classiﬁed either as
recent or older as deﬁned under methods. The BED-EIA
classiﬁed 127 of the recent 195 infections as recent,
exhibiting 65% sensitivity. The low sensitivity of the BED-
EIA is due to the longer duration of the interval deﬁned
recent (12 mo in this study compared to 153 d in other studies
using this test) [2,3,14]. The BED-EIA also classiﬁed 129 of the
161 older infections as older, exhibiting 80% speciﬁcity.
Overall correct results amounted to 72%, the diagnostic odds
ratio was 7.4, and the logistic likelihood ratio (LLR) Chi-
square was 78.7 (Table 1).
Univariate logistic regression analysis showed that a low
antibody score to any of the ﬁve HIV-1 antigen bands of the
INNO-LIA strip was associated signiﬁcantly with recent
infection (p , 0.0001 for all, data not shown). Algorithms
(Alg) 2–6 in Table 1 demonstrate the best power to
discriminate between recent and older infection, as indicated
by the highest LLR Chi-square achieved when varying the
band intensity cut-off. Some of these algorithms exhibited
similar or superior strength compared to BED-EIA, as shown
by higher diagnostic odds ratios and LLRs. Alg2–6 were
considerably more speciﬁc than was BED-EIA, but their
sensitivities were lower, thus resulting in an overall lower
percentage of correct results for INNO-LIA than for BED-
EIA.
When using bands in combination and again optimizing
cutoffs by means of logistic regression analysis, algorithms
with around 98% speciﬁcity and 40% sensitivity were
developed (Alg7–9). Based on the observation that serocon-
version to p31 in Western blot occurs consistently later than
to p24 [15,16], we also assessed this criterion alone (Alg10) or
in combination (Alg11–13). Despite being a rather weak
criterion on its own, Alg10 strongly increased sensitivity,
albeit at some cost to speciﬁcity, when added to other
criteria. Overall correct results by Alg11–13 amounted to
around 70%, which was comparable to BED-EIA (72%).
Multivariate logistic regression analysis adjusting for sex,
transmission risk, and INNO-LIA reading mode (visual or
automated) demonstrated no impact of these variables on the
strength of the algorithms (unpublished data). Moreover, the
reading mode had no signiﬁcant impact on the INNO-LIA
result. Although automated reading was associated with
overall slightly lower intensity scores (p ¼ 0.005, Mann-
Whitney U test), probably due to the fact that the Liras
software counts a score of 4 as 3, this reduction in mean
scores had no impact on an algorithm’s outcome, as an
algorithm’s cutoff is always placed at lower scores. For Alg12,
for example, the odds ratio for automated versus visual
reading for ruling an infection as recent was 1.11 (95%
conﬁdence interval [CI] 0.76–1.62; p¼0.60). There was also no
difference in the case of single-band algorithms.
Recency Rates in Different Patient Groups and Test
Concordance
The proportion of patients ruled to have been infected
recently by BED-EIA or INNO-LIA and the concordance of
the two procedures in the different patient groups is shown
in Table 2. Alg12 was selected for this comparison due to its
overall highest rate of correct results (compare to Table 1). In
all groups, BED-EIA found considerably more samples recent
than did Alg12. Concordance between the two procedures
was lowest among recent infections (74%) and highest in CDC
stage C (86%). Note again that the relatively low sensitivity of
the BED-EIA compared to other studies is due to the longer
duration of the interval deﬁned recent in this study.
We next investigated the sensitivity of selected algorithms
of Table 1 for detection of the early, intermediate, or late
phase of recent infection, as established in Figure 1B. The
sensitivity of BED-EIA and all INNO-LIA algorithms de-
creased from early to intermediate to late phase (Table 3). In
the early phase, INNO-LIA algorithms were similar in
sensitivity to BED-EIA. In the intermediate and particularly
the late phases of recent infection, INNO-LIA was consid-
erably less sensitive than BED-EIA. Thus, the overall higher
Table 3. Percent Sensitivity of Various Recency Algorithms at
Different Phases of Recent Infection
Algorithm Early Phasea
(n ¼ 46)
Intermediate
Phaseb (n ¼ 100)
Late Phasec
(n ¼ 49)
Alg1 76 64 57
Alg3 52 15 0
Alg9 70 41 10
Alg12 78 52 20
aCases meeting recency definition 3 or both 1 and 2.
bCases meeting recency definition 1, but not 2 or 3.
cCases meeting recency definition 2, but not 1 or 3.
doi:10.1371/journal.pmed.0040343.t003
Table 4. Estimation of the Overall Recent Infection Rate in the Study
Test Tested Recent, n Model 1 (Unadjusted) Model 2 (Adjusted)
Recent Infection Ratea Cases Estimated Recent Recent Infection Rateb Cases Estimated Recent
BED-EIA 262 0.33 250 0.37 278
Alg12 130 0.27 204 0.35 260
Alg9 88 0.27 204 0.33 250
Alg3 39 0.26 195 0.26 195
aEstimate based on the equation Recency Rate¼ (ntested recent/ntested þ%Specificity/100 – 1) / (%Sensitivity/100þ%Specificity/100 – 1).
bEstimate based on the same equation, but using the reduced sensitivities of Table 4, last column, for the unknown group.
doi:10.1371/journal.pmed.0040343.t004
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sensitivity of BED-EIA in Table 1 was due to its better
recognition of the intermediate and late phases of recent HIV
infection.
Estimation of the Recent Infection Rate in the Entire Study
Population
Given the more than 50% cases without reference recency
information, the true proportion of recent infections
(infections that occurred within the past 12 mo) in the study
population was unknown. We estimated this value on the
basis of the results of the different recency tests in the entire
study population. The equation used for these estimates (see
Methods) adjusts for a test’s sensitivity and speciﬁcity, as
determined in Tables 1 and 3.
The BED-EIA ruled 262 (35.3%) of the 748 infections as
recent. When entering the sensitivity and speciﬁcity deter-
mined in Table 1 into the equation, a proportion of 33%
recent infections corresponding to 250 cases was calculated
(Table 4, model 1). Recency estimates by Alg12 and Alg9 were
markedly lower, but yielded identical results to each other
(27%, 204 cases), despite their considerable difference in the
actual number of infections diagnosed as recent (130 versus
88). For Alg3 which according to Table 3 identiﬁes only early
recent infections and did not detect any further recent cases
outside the group deﬁned as recent, the estimate was
remarkably close (26%).
Application of the sensitivity and speciﬁcity rates of the
reference group of Table 1 to the unknown group is, however,
feasible only if both groups are composed similarly; otherwise
bias is introduced. Figure 1B shows that there is indeed
considerable heterogeneity. Regarding their overall antibody
reaction the unknown group differs signiﬁcantly from the
reference group of Table 1 (Mann-Whitney U test, p , 0.001).
The unknown group has very little overlap with the early and
intermediate phases of recent infection (Figure 1B). Thus, if
the nonclassiﬁed infections include any recent infections at
all, these are likely to be in the late phase of recent infection.
It is therefore appropriate to use the reduced sensitivity rates
shown in the last column of Table 3 for this group. Speciﬁcity,
in contrast, was very similar among the different groups, in
particular as regards INNO-LIA (cf. Table 2). Hence, by doing
a mixed calculation, i.e., applying the sensitivity of Table 1 to
the reference group and the reduced sensitivity of late recent
infection of Table 3 to the unknown group while applying the
speciﬁcity of Table 1 to both groups, we obtained more
appropriate estimates for the recent infection rate of the
entire study (Table 4, model 2). Compared with model 1 the
adjusted model 2 showed an only 12% higher rate of recent
infections for the BED-EIA, but as much as 20%–30% higher
rates for Alg9 and Alg12, in agreement with the fact that the
sensitivity of BED-EIA is reduced less in the late phase of
recent infection than is the sensitivity of INNO-LIA (compare
to Table 3). With recency rates of 0.35 and 0.33, respectively,
Alg12 and Alg9 now showed good agreement with BED-EIA
(0.37), while the estimate by Alg3, which does not detect cases
in the late phase of recent infection, remained unchanged at
0.26. Alg3 clearly underestimated recent infection.
Window Periods and Window-Based Estimation of the
Recency Rate
In order to determine the window periods of the different
INNO-LIA algorithms we analyzed INNO-LIA results of 15
seroconversion panels (Table 5; see also Methods). Alg3 (gp41)
was associated with the shortest window period among the
single band algorithms, followed by Alg5 (p24), Alg6 (p17),
Alg2 (sgp120), and Alg4 (p31). The time span of many panels
was shorter than the window period of many algorithms. The
resulting window information is thus based on too few
Table 5. INNO-LIA Window Periods Derived from Seroconversion
Panels and Estimates for the Recent Infection Rate
Alg # Window, Days,
Mean (95% CI)
Applicable
Seroconversion
Panels, n
Tested
Recent,
n
Recent Infection
Ratea, Mean
(95% CI)
1 153 N/A 127 0.41 (0.36–0.46)
2 49 (39–59) 8 81 0.81 (0.67–1.01)
3 36 (29–43) 15 39 0.53 (0.44–0.66)
4 59 (42–76) 6 96 0.79 (0.62–1.12)
5 38 (31–45) 14 41 0.53 (0.44–0.65)
6 44 (34–54) 9 64 0.71 (0.58–0.92)
7 49 (39–59) 8 79 0.79 (0.65–0.99)
8 49 (39–59) 8 81 0.81 (0.67–1.01)
9 48 (39–57) 9 78 0.79 (0.67–0.98)
10 50 (50–50) 2 47 0.46 (N/A)
11 49 (29–69) 4 97 0.97 (0.69–1.63)
12 67 (48–86) 2 98 0.71 (0.56–1.00)
13 59 (42–76) 3 95 0.79 (0.61–1.10)
aRecent Infection Rate¼ (nrecent/748)3 (365/Window).
bInformation provided by the kit manufacturer.
N/A, not applicable.
doi:10.1371/journal.pmed.0040343.t005
Table 6. Characteristics of the Study Population
Criterion Category n %
Total number 748 100
Male 454 60.7
Female 227 30.3
No information 67 9.0
Mode of
transmission
Men who have sex
with men (MSM)
244 32.6
Intravenous drug use (IDU) 54 7.2
Heterosexual 298 39.8
Other or unknown 152 20.3
Classified as
recent infectiona
Recency definition
1: Symptoms of PHI
100 13.4
Recency definition
2: History of negative HIV test
49 6.6
Recency definitions 1 and 2 26 3.5
Recency definition
3: Negative or indeterminate
HIV antibodies
20 2.7
Total 195 26.1
Classified as
older infectiona
Symptoms of CDC stage B 84 11.2
Symptoms of CDC stage C 77 10.3
Total 161 21.5
Not classified CDC stage A 252 33.7
No information 140 18.7
Total 392 52.4
aSee Methods for classifications.
doi:10.1371/journal.pmed.0040343.t006
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measurements and not reliable. Nevertheless, we tentatively
used this information for an independent estimation of the
recent infection rate in our study population. With this
approach, BED-EIA yielded a rate of 0.41 compared to 0.37
obtained by model 2 of Table 5. Alg3 (gp41) and Alg5 (p24),
whose window periods are the most reliable, both yielded a
rate of 0.53. Other INNO-LIA algorithms supported less well
by seroconversion panel results yielded rates of up to 0.98,
thus conﬁrming that the respective windows are indeed too
short.
Discussion
We demonstrate that a patient’s antibody reaction in the
INNO-LIA HIV I/II Score assay contains information which,
similar to the Calypte BED-EIA, allows a distinction to be
made between recent and older HIV-1 infection, thus
providing a tool for estimating HIV-1 incidence in a
population. Because antibody reactions to the ﬁve HIV-1
antigens measured by the INNO-LIA evolve over time after
the infection (Figure 1), we evaluated various algorithms for
their ability to distinguish between recent and older infection
in a cohort of 748 unselected HIV-1 infected patients newly
diagnosed during a period of 12 mo in Switzerland. The best
INNO-LIA algorithms ruled 40%–50% of the 195 infections
deﬁned as being recent (up to 12 mo duration of infection) as
recent, while ruling 95%–99% of the 161 infections deﬁned
as being older as older. In comparison, a dedicated
commercial recency test, the BED-EIA, ruled 65% of the
recent samples as recent and 80% of the older samples as
older (Table 1). Concordance of the two tests was 74%–86%
based on stage (Table 2). Both tests exhibited about 80%
sensitivity for the early phase of recent infection, while
showing reduced sensitivity for the intermediate and,
particularly, late phases of recent infection (Table 3). Based
on the sensitivity and speciﬁcity rates thus obtained from
patients of known recency status we estimated the proportion
of recent infections in the entire cohort of 748 patients.
Utilizing an adjusted model we obtained recency rates of 0.33
and 0.35 for two INNO-LIA algorithms and of 0.37 for the
BED-EIA (Table 4), which was similar to the window-based
estimate of 0.41 for the BED-EIA (Table 5). There was higher
discrepancy for the INNO-LIA algorithms, due to still-
unreliable window period estimates.
All STARHS reported to date utilize window periods, i.e.,
the mean time from infection to the ﬁrst positive result of a
test. Based on the number of cases ruled recent in a tested
population and the length of the window period the annual
incidence can be calculated. The approach in our study is
fundamentally different. Based on reference information
obtained from the treating physicians we ﬁrst deﬁned two
subsets of patients. One subset consisted of patients infected
within 12 mo prior to HIV diagnosis (recent infection), and
the other of patients who had older infections based on
symptoms of CDC stage B or C. We used these two reference
subsets to determine the sensitivity and speciﬁcity of various
recency algorithms (Tables 1–3). Based on the now-known
sensitivity and speciﬁcity and the number of cases ruled
recent by a given algorithm the proportion of recent
infections in the entire study population was calculated
(Table 4). Thus, while the classical STARHS approach
requires reliable window information for the test but no
clinical information on the patients tested, our approach
requires reliable clinical reference information for a sub-
group of patients but no window information for the test.
During seroconversion, an HIV-infected person progresses
from seronegativity to a pattern of full reactivity to all major
HIV proteins [15]. Deﬁning HIV seroconversion or recent
infection as anything less than a full antibody reaction
pattern may thus seem trivial. However, as disease progres-
sion is associated with decreasing concentrations of many
antibodies, there is a second, late phase in HIV infection with
incomplete patterns or submaximal concentrations of anti-
bodies [12,13,17–20]. The detection of patients in recent
infection by means of differential antibody reactivity thus
requires a careful optimization of candidate algorithms with
the aim to maximize correct assessment. The best INNO-LIA
algorithms compared well with the BED-EIA regarding power
to discriminate between recent and older infection and were
considerably more speciﬁc than the BED-EIA (Table 1).
Unlike the BED-EIA, which due to its deliberately reduced
sensitivity compared to HIV screening tests has no role in the
diagnosis of HIV infection, the INNO-LIA is an excellent test
for conﬁrmation of HIV infection and is superior to (and less
expensive than) Western blot for differentiating between
HIV-1 and HIV-2 infection [9,10]. Early identiﬁcation of HIV-
2 infection is becoming increasingly important, as HIV-2
cannot be quantitated by any of the FDA-approved tests for
HIV-1 RNA measurement [21] and is naturally resistant to
several commonly used antiretroviral drugs [22–25]. The
INNO-LIA HIV I/II Score assay is CE marked, i.e., approved
for diagnostic use in the European Union, but currently
cannot be used in the US, as the test is not FDA approved.
INNO-LIA based STARHS is not a reasonable option for low-
resource countries that use less expensive combinations of
HIV screening tests for conﬁrmation of HIV infection.
The recency information provided by the INNO-LIA comes
at no additional costs and can be integrated easily into
existing national HIV reporting systems. The number of cases
for which recency information is available will thus be higher
than in systems in which recency information must be gained
from costly epidemiologic studies. This fact should result in
HIV-1 incidence estimates of overall higher quality. The
multicenter nature of the present study and the employment
of both visual and automated strip evaluation in the 12
collaborating labs, with no apparent impact on the result,
suggests that INNO-LIA-based recency assessment can be
transferred to other labs without loss of quality. Studies to
clarify this point and to determine whether automated
reading is advantageous are currently underway.
In order to obtain an independent estimate of the recent
infection rate in our study we also used a window-based
approach (Table 5). The resulting infection rate of 0.41 of the
BED-EIA was remarkably close to the 0.37 obtained by the
adjusted model in Table 4. This agreement of results suggests
that, by and large, the information from the physicians was
reliable, although we cannot exclude the possibility of
misclassiﬁcation. For example, some PHI cases presenting
with severe clinical manifestations may have been misclassi-
ﬁed as older infections [26–29]. Altogether, the window based
recency assessment by the BED-EIA however validates the
sensitivity/speciﬁcity-based approach.
As the time span covered by many of the seroconversion
panels was too short, sufﬁciently accurate window informa-
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tion is still lacking for most INNO-LIA algorithms. For Alg3
(gp41) and Alg5 (p24), window periods of 36 d and
respectively 38 d were obtained, which is considerably shorter
than the 153 d of the BED-EIA and consistent with the low
sensitivity of INNO-LIA for the intermediate and late phases
of recent infections (Table 3). Alg3 and Alg5 yielded an
identical recent infection rate of 0.53, which is somewhat
higher than that of BED-EIA (0.41). As the window periods
are very short, a few days’ difference can have a big effect
when calculating an annual rate. For example, increasing the
window periods of Alg3 or Alg5 by 6 d, as would result from
using an average seroconversion interval of 28 d instead of 22
d (see Methods), would reduce the rate from 0.53 to 0.45.
Testing of further panels covering extended time periods
thus is urgently needed to deﬁne longer INNO-LIA windows
with sufﬁcient accuracy. Once established, window-based
recency estimates will also be feasible for INNO-LIA
algorithms and probably represent the preferred method.
Different algorithms will also be usable in combination,
which should result in more reliable estimates.
Limitations
A possible current limitation of INNO-LIA-based recency
testing may derive from the inﬂuence of infections by non-B
subtypes of HIV-1. Like other European countries, Switzer-
land has a high rate of non-B infections [30] and the
proportion of such viruses among newly diagnosed HIV-1
infections has now reached proportions of two-thirds in
women and one-third in men (unpublished data from the
Swiss genotypic resistance test database). Patients infected
with such viruses may produce antibodies of reduced avidity
to the subtype B antigens frequently employed in diagnostic
tests, thus leading to low-reactivity patterns when tested and
subsequent false diagnosis of recent infections. Such an effect
has been observed with several early STARHS tests [31,32].
The BED-EIA, developed in order to overcome this problem,
therefore features a branched peptide consisting of the
immunodominant gp41 B-cell epitope of subtypes B, D, and E
[3]. The fact that all INNO-LIA based algorithms were
considerably more speciﬁc than the BED-EIA suggests that
subtype interference should be less a problem for the INNO-
LIA than it is for the BED-EIA. Systematic studies are planned
to clarify this point.
Another known factor which may impair the speciﬁcity of
STARHS consists of the reduced antibody concentrations
associated with advanced disease stage (Figure 1). A further
problem consists of cases that never reach a sufﬁciently high
optical density to qualify as older infection [33]. The Joint
United Nations Programme on HIV/AIDS Epidemiology
Reference Group has recently issued a warning that the
BED-EIA may overestimate HIV-1 incidence and should not
be used for routine surveillance applications, and other
investigations have also reported overestimation [14,34]. As
the speciﬁcity of INNO-LIA based algorithms in patients with
reported symptoms of AIDS is already high (Table 2), this
concern should not be a problem for INNO-LIA. Never-
theless, studies addressing this question by means of well
characterized patients of the Swiss HIV Cohort Study (SHCS)
are planned.
As shown by Figure 1B, the nonclassiﬁed infections differ as
group from the classiﬁed infections. Application of the
sensitivity and speciﬁcity rates of the reference classiﬁed
group to the unknown group will thus introduce bias. As a
consequence, model 1 of Table 4, which does not correct for
such bias, clearly underestimates the overall rate of recent
infections. Although model 2 of Table 4 adjusts for the
discrepancy, it is possible that the model still underestimates
the true proportion of recent infections in the unknown
group and, thus, the entire study population. Given the small
difference between window-based and sensitivity/speciﬁcity-
based recency rate estimates (0.41 compared to 0.37 for the
BED-EIA), the inﬂuence of such possible further bias in the
present study should be small, however. Nevertheless, as
window-based recency assessment does not require knowl-
edge of group composition, it should be the preferred
method of INNO-LIA based recency assessment once
INNO-LIA windows have been established with sufﬁcient
precision. Window-based recency assessment should also
facilitate transfer of the method to other populations.
In conclusion, we provide proof of principle that a well-
standardized line immunoassay for HIV conﬁrmation and
type differentiation also contains information on whether an
HIV-1 infection is recent. The recency information provided
by the INNO-LIA HIV I/II Score is available at no additional
expenditure to countries in which this test is routinely used
for conﬁrmation of an HIV infection and HIV type differ-
entiation. Utilization of this information could improve HIV
surveillance in such countries. Because reliable window
periods for INNO-LIA algorithms have not yet been
established, INNO-LIA based recency assessment is currently
restricted to the sensitivity/speciﬁcity approach described
here. As the sensitivity and speciﬁcity of INNO-LIA algo-
rithms may vary between different populations, it will be
necessary to assess them anew when transferring the method
to a different study population. Additional studies are needed
to establish reliable window periods for the different INNO-
LIA algorithms, to clarify the inﬂuence of HIV-1 subtype, and
to further assess the speciﬁcity of the method in advanced
disease.
Supporting Information
Text S1. Flow Chart
Found at doi:10.1371/journal.pmed.0040343.sd001 (26 KB PPT).
Text S2. STARD Checklist
Found at doi:10.1371/journal.pmed.0040343.sd002 (258 KB PPT).
Acknowledgments
The authors acknowledge the assistance of Katrin Steinbeck in this
work and are grateful to Dr. Leslie R. Bisset for critical reading of the
manuscript. The corresponding author, Jo¨rg Schu¨pbach, supplied the
information regarding Bruno Gu¨ntert’s contribution to the manu-
script and his competing interests and it is correct to the best of his
knowledge.
Author contributions. JS, RS, and PV designed the study. JS, MDG,
DS, and PV analyzed the data. JS, ZT, CN, SY, PB, LM, MG, RD, DS, IS,
CA, BM, and BG enrolled patients. JS, SY, PB, LM, MG, DS, and PV
contributed to writing the paper. MDG, ZT, CN, SY, PB, LM, MG, RD,
DS, IS, CA, GM, BG, SD, and PV collected data or performed
experiments for this study. MDG contributed the clinical data (from
surveillance) needed for the analysis. Patients included in the present
study are based on patients enrolled in the CHAT study, which
included all individuals with a newly diagnosed HIV infection for the
duration of 1 year. SD and PV were responsible for the design, data
collection, and summary of the CHAT study, of which some results
are presented in the present study.
PLoS Medicine | www.plosmedicine.org December 2007 | Volume 4 | Issue 12 | e3431928
Assessment of Recent HIV-1 Infection
References
1. Janssen RS, Satten GA, Stramer SL, Rawal BD, O’Brien TR, et al. (1998) New
testing strategy to detect early HIV-1 infection for use in incidence
estimates and for clinical and prevention purposes. JAMA 280: 42–48.
2. Parekh BS, McDougal JS (2005) Application of laboratory methods for
estimation of HIV-1 incidence. Indian J Med Res 121: 510–518.
3. Parekh BS, Kennedy MS, Dobbs T, Pau CP, Byers R, et al. (2002)
Quantitative detection of increasing HIV type 1 antibodies after
seroconversion: a simple assay for detecting recent HIV infection and
estimating incidence. AIDS Res Hum Retroviruses 18: 295–307.
4. Schupbach J, Popovic M, Gilden RV, Gonda MA, Sarngadharan MG, et al.
(1984) Serological analysis of a subgroup of human T-lymphotropic
retroviruses (HTLV-III) associated with AIDS. Science 224: 503–505.
5. Sarngadharan MG, Popovic M, Bruch L, Schupbach J, Gallo RC (1984)
Antibodies reactive with human T-lymphotropic retroviruses (HTLV-III) in
the serum of patients with AIDS. Science 224: 506–508.
6. [No author listed] (2006) Das schweizerische HIV-Testkonzept—aktuali-
sierte Uebersicht u¨ber Technisches Konzept und Laborkonzept. BAG
Bulletin: 22–34. Available: http://www.bag.admin.ch/dokumentation/
publikationen/01435/01795/index.html?lang¼de. Accessed 7November 2007.
7. fNo author listed] (1993) From the Centers for Disease Control and
Prevention. 1993 revised classiﬁcation system for HIV infection and
expanded surveillance case deﬁnition for AIDS among adolescents and
adults. JAMA 269: 729–730.
8. Hecht FM, Busch MP, Rawal B, Webb M, Rosenberg E, et al. (2002) Use of
laboratory tests and clinical symptoms for identiﬁcation of primary HIV
infection. AIDS 16: 1119–1129.
9. Pollet DE, Saman EL, Peeters DC, Warmenbol HM, Heyndrickx LM, et al.
(1991) Conﬁrmation and differentiation of antibodies to human immuno-
deﬁciency virus 1 and 2 with a strip-based assay including recombinant
antigens and synthetic peptides. Clin Chem 37: 1700–1707.
10. Walther L, Putkonen P, Dias F, Biberfeld G, Thorstensson R (1995)
Evaluation of HIV-1/HIV-2 immunoblots for detection of HIV-2 antibodies.
Clin Diagn Virol 4: 67–79.
11. Busch MP, Satten GA (1997) Time course of viremia and antibody
seroconversion following human immunodeﬁciency virus exposure. Am J
Med 102: 117–124.
12. Lange JM, Goudsmit J, De Wolf F, Coutinho RA, van der Noordaa J (1988)
Serological markers in HIV infection. Ann Med Interne (Paris) 139: 80–83.
13. Schupbach J, Haller O, Vogt M, Luthy R, Joller H, et al. (1985) Antibodies to
HTLV-III in Swiss patients with AIDS and pre-AIDS and in groups at risk
for AIDS. N Engl J Med 312: 265–270.
14. Karita E, Price M, Hunter E, Chomba E, Allen S, et al. (2007) Investigating
the utility of the HIV-1 BED capture enzyme immunoassay using cross-
sectional and longitudinal seroconverter specimens from Africa. AIDS 21:
403–408.
15. Fiebig EW, Wright DJ, Rawal BD, Garrett PE, Schumacher RT, et al. (2003)
Dynamics of HIV viremia and antibody seroconversion in plasma donors:
implications for diagnosis and staging of primary HIV infection. AIDS 17:
1871–1879.
16. Lindback S, Thorstensson R, Karlsson AC, von Sydow M, Flamholc L, et al.
(2000) Diagnosis of primary HIV-1 infection and duration of follow-up
after HIV exposure. Karolinska Institute Primary HIV Infection Study
Group. AIDS 14: 2333–2339.
17. Lange JM, de Wolf F, Krone WJ, Danner SA, Coutinho RA, et al. (1987)
Decline of antibody reactivity to outer viral core protein p17 is an earlier
serological marker of disease progression in human immunodeﬁciency
virus infection than anti-p24 decline. AIDS 1: 155–159.
18. Pedersen C, Nielsen CM, Vestergaard BF, Gerstoft J, Krogsgaard K, et al.
(1987) Temporal relation of antigenaemia and loss of antibodies to core
antigens to development of clinical disease in HIV infection. Br Med J (Clin
Res Ed) 295: 567–569.
19. Schmidt G, Amiraian K, Frey H, Stevens RW, Berns DS (1987) Densito-
metric analysis of Western blot (immunoblot) assays for human immuno-
deﬁciency virus antibodies and correlation with clinical status. J Clin
Microbiol 25: 1993–1998.
20. Manca N, di Marzo Veronese F, Ho DD, Gallo RC, et al. (1987) Sequential
changes in antibody levels to the env and gag antigens in human
immunodeﬁciency virus infected subjects. Eur J Epidemiol 3: 96–102.
21. Schu¨pbach J (2003) Human imunodeﬁciency viruses. In: Murray PR, Baron
EJ, Jorgenson JH, Pfaller MA, Yolken RH, editors. Manual of clinical
microbiology. 8th Ed. Washington (D. C.): ASM Press. pp. 1253–1281.
22. Tuaillon E, Gueudin M, Lemee V, Gueit I, Roques P, et al. (2004) Phenotypic
susceptibility to nonnucleoside inhibitors of virion-associated reverse
transcriptase from different HIV types and groups. J Acquir Immune
Deﬁc Syndr 37: 1543–1549.
23. Ntemgwa M, Brenner BG, Oliveira M, Moisi D, Wainberg MA (2007) Natural
polymorphisms in the human immunodeﬁciency virus type 2 protease can
accelerate time to development of resistance to protease inhibitors.
Antimicrob Agents Chemother 51: 604–610.
24. Parreira R, Monteiro F, Padua E, Piedade J, Venenno T, et al. (2006) Natural
polymorphisms of HIV type 2 pol sequences from drug-naive individuals.
AIDS Res Hum Retroviruses 22: 1178–1182.
25. Reid P, MacInnes H, Cong ME, Heneine W, Garcia-Lerma JG (2005) Natural
resistance of human immunodeﬁciency virus type 2 to zidovudine. Virology
336: 251–264.
26. Berger DS, Bucher G, Nowak JA, Gomatos PJ (1996) Acute primary human
immunodeﬁciency virus type 1 infection in a patient with concomitant
cytomegalovirus encephalitis. Clin Infect Dis 23: 66–70.
27. Tindall B, Hing M, Edwards P, Barnes T, Mackie A, et al. (1989) Severe
clinical manifestations of primary HIV infection. AIDS 3: 747–749.
28. Vento S, Di Perri G, Garofano T, Concia E, Bassetti D (1993) Pneumocystis
carinii pneumonia during primary HIV-1 infection. Lancet 342: 24–25.
29. Tattevin P, Camus C, Arvieux C, Ruffault A, Michelet C (2007) Multiple
organ failure during primary HIV infection. Clin Infect Dis 44: e28–29.
30. Boni J, Pyra H, Gebhardt M, Perrin L, Burgisser P, et al. (1999) High
frequency of non-B subtypes in newly diagnosed HIV-1 infections in
Switzerland. J Acquir Immune Deﬁc Syndr 22: 174–179.
31. Parekh BS, Hu DJ, Vanichseni S, Satten GA, Candal D, et al. (2001)
Evaluation of a sensitive/less-sensitive testing algorithm using the 3A11-LS
assay for detecting recent HIV seroconversion among individuals with
HIV-1 subtype B or E infection in Thailand. AIDS Res Hum Retroviruses
17: 453–458.
32. Young CL, Hu DJ, Byers R, Vanichseni S, Young NL, et al. (2003) Evaluation
of a sensitive/less sensitive testing algorithm using the bioMerieux
Vironostika-LS assay for detecting recent HIV-1 subtype B’ or E infection
in Thailand. AIDS Res Hum Retroviruses 19: 481–486.
33. McDougal JS, Parekh BS, Peterson ML, Branson BM, Dobbs T, et al. (2006)
Comparison of HIV type 1 incidence observed during longitudinal follow-
up with incidence estimated by cross-sectional analysis using the BED
capture enzyme immunoassay. AIDS Res Hum Retroviruses 22: 945–952.
34. Anonymous (2006) UNAIDS Reference Group on Estimates, Modelling and
Projections: statement on the use of the BED assay for the estimation of
HIV-1 incidence for surveillance or epidemic monitoring. Wkl Epid Rec 81:
40.
PLoS Medicine | www.plosmedicine.org December 2007 | Volume 4 | Issue 12 | e3431929
Assessment of Recent HIV-1 Infection
Editors’ Summary
Background. Since the first diagnosed cases of AIDS (acquired
immunodeficiency syndrome) in 1981, the AIDS epidemic has spread
rapidly. Now, 40 million people are infected with HIV (human
immunodeficiency virus), the cause of AIDS. HIV infects and kills immune
system cells, leaving infected individuals susceptible to other infectious
diseases and tumors. The first, often undiagnosed, stage of HIV infection
(primary HIV infection) lasts a few weeks and often involves a flu-like
illness. During this stage, the immune system begins to respond to HIV
by producing antibodies (proteins that recognize viral molecules called
antigens). The time needed for these antibodies to appear on testing
‘‘seroconversion’’ (usually 6–12 weeks) is called the window period of
the test; HIV antibody tests done during this period give false negative
results. During the second, symptom-free stage of HIV infection, which
can last many years, the virus gradually destroys the immune system so
that by the third stage of infection unusual infections (for example,
persistant yeast infections of the mouth) begin to occur. The fourth stage
is characterized by multiple AIDS-indicator conditions such as severe
bacterial, fungal, or viral infections, and cancers such as Kaposi sarcoma.
Why Was This Study Done? To monitor the AIDS/HIV epidemic and HIV
prevention programs, it is necessary to know how many people in a
population have been recently infected with HIV. Serologic testing
algorithms for recent HIV seroconversion (STARHS) provide a way to get
this information. Early during seroconversion, low levels of antibodies
that bind only weakly to their viral antigens (low-affinity antibodies) are
made. Later on, antibody concentrations and tightness of binding
increase. STARHS calculate the number of recently infected people by
analyzing data from special ‘‘detuned’’ HIV antibody assays (for example,
a commercially available test called the BED-EIA) that preferentially
detect low-concentration, low-avidity antibodies. This type of test
cannot, however, be used to determine whether an individual has an
HIV infection, because it will miss a substantial fraction of infected
people. Diagnosing HIV in an individual person requires more sensitive
tests for antibody detection. In this study, the researchers have
investigated whether a test called INNO-LIA, which is already being
used in some countries to diagnose HIV infection, can also provide
information about the recency (newness) of HIV infections.
What Did the Researchers Do and Find? Between July 2005 and June
2006, 765 HIV infections were newly diagnosed in Switzerland. Using
clinical and laboratory information collected at diagnosis, the researchers
classified 195 of these infections as recent infections (occurring within
the past year) and 161 as older infections. (The remaining infections
could not be classified based on the available medical infomation.) The
researchers then compared the ability of INNO-LIA (which measures
antibodies to five HIV-1 antigens) and BED-EIA to distinguish recent from
older HIV infections. BED-EIA correctly identified as recent 65% of the
infections classified as recent based on the clinical information, and
identified as older 80% of the infections classified as older based on the
clinical information. In other words, this test was 65% sensitive (able to
detect 65% of the truly recent infections as defined in this study) and was
80% specific (80% accurate in eliminating non-recent infections.) The two
best algorithms (mathematical procedures) for converting INNO-LIA data
into estimates of recent HV infections had sensitivities of 50% and 40%
and specificities of 95% and 99%, respectively. Using actual test results
and taking into account these sensitivities and specificities gave
estimates of 35% and 33% for the proportion of the whole study
population that had been recently infected. BED-EIA gave an estimate of
37%. Finally, a widely used window-based algorithm for recency
estimation that uses the numbers of cases that are defined as recent
by BED-EIA and the length of the window period for BED-EIA to calculate
the annual number of new infections in populations indicated that 41%
of the whole study population had been recently infected.
What Do These Findings Mean? These findings indicate that numbers
of recent HIV infections can be extracted from the INNO-LIA HIV
diagnostic test and are comparable to those obtained using a window-
based algorithm. The test could, therefore, provide a cost-effective
means to improve HIV surveillance in countries like Switzerland that
already use it for HIV diagnosis. However, because this approach relies
on knowing the sensitivity and specificity of the INNO-LIA algorithms,
which may vary between populations, the use of these algorithms to
estimate numbers of recent HIV infections must be preceded by an
assessment of their sensitivity and specificity in each new setting.
Additional Information. Please access these Web sites via the online
version of this summary at http://dx.doi.org/10.1371/journal.pmed.
0040343.
 HIV InSite has comprehensive information on all aspects of HIV/AIDS,
including fact sheets on the symptoms of HIV infection, HIV testing,
and a chapter on laboratory tests for HIV antibodies
 NAM, a UK registered charity, provides information about all aspects of
HIV and AIDS, including fact sheets on the stages of HIV infection and
HIV testing
 The US Centers for Disease Control and Prevention (CDC) provides
information on HIV/AIDS, including information on HIV testing and on
HIV surveillance by the CDC (in English and Spanish)
 Information is available from Avert, an international AIDS charity, on
the stages of HIV infection and on HIV testing
 Details on the US Centers for Disease Control and Prevention and the
World Health Organiztion HIV classification systems are available from
the US Department of Veterans Affairs
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